Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 8NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 13Gastrointestinal 3Head & Neck 2Breast 2Sarcoma 1Lymphoid 1

Conditions

Sarcoma 1Mycosis Fungoides 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × talimogene laherparepvec × Sarcoma × Clear all
NCT02890368 2023-04-05

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Pfizer

Phase 1 Terminated
56 enrolled
BreastDermatologicLymphoidSarcoma

Breast Neoplasms, Carcinoma, Squamous Cell, Melanoma, Mycosis Fungoides, Sarcoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡